Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911157 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL9181091 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL38656174 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL31207037 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL44896 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL402299 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL9207279 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL18169171 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL130471 | 0.97 | OPRM1 (0.52) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL671923 | 0.89 | OPRM1 (0.46) | OPRM1TSHRTHRBSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1933813-A | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO LTD (AU) | 2007-03-21 | — | — | CN | claimed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| CN-104114569-A | Oligonucleotide with protected base moiety | AJINOMOTO KK | 2014-10-22 | — | — | CN | disclosed |
| CN-1933813-A | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO LTD (AU) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | OPRM1 4472/4885TSHR 3319/4885THRB 1824/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | OPRM1 4472/4885TSHR 3319/4885THRB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.